{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma%2C+Hodgkin&page=9", "query": { "condition": "Lymphoma, Hodgkin", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 3814, "total_pages": 382, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma%2C+Hodgkin&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma%2C+Hodgkin&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T00:03:05.400Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02793583", "title": "Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Diffuse Large B-Cell Lymphoma", "Follicular Lymphoma", "Marginal Zone Lymphoma", "Mantle Cell Lymphoma", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Ublituximab", "type": "BIOLOGICAL" }, { "name": "Umbralisib", "type": "DRUG" }, { "name": "Bendamustine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "TG Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 710, "start_date": "2016-05-25", "completion_date": "2022-07-04", "has_results": false, "last_update_posted_date": "2022-07-21", "last_synced_at": "2026-10-15T00:03:05.400Z", "location_count": 111, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 97 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02793583" }, { "nct_id": "NCT02879695", "title": "Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent B Acute Lymphoblastic Leukemia", "Recurrent Mixed Phenotype Acute Leukemia", "Refractory B Acute Lymphoblastic Leukemia", "Refractory Mixed Phenotype Acute Leukemia" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Blinatumomab", "type": "BIOLOGICAL" }, { "name": "Bone Marrow Aspiration and Biopsy", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 28, "start_date": "2017-10-25", "completion_date": "2027-07-18", "has_results": true, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-10-15T00:03:05.400Z", "location_count": 7, "location_summary": "New Haven, Connecticut • Lexington, Kentucky • Baltimore, Maryland + 4 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02879695" }, { "nct_id": "NCT00161239", "title": "LAMPP Trial for Peripheral and Cutaneous T-Cell Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "T-Cell Lymphoma" ], "interventions": [ { "name": "Doxil, Methotrexate, L-Asparaginase, Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Medicine and Dentistry of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2005-02", "completion_date": "2007-10", "has_results": false, "last_update_posted_date": "2009-12-11", "last_synced_at": "2026-10-15T00:03:05.400Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00161239" }, { "nct_id": "NCT02051257", "title": "Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Mantle Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Mantle Cell Lymphoma", "Transformed Recurrent Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells", "type": "BIOLOGICAL" }, { "name": "Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2014-06-19", "completion_date": "2027-03-02", "has_results": false, "last_update_posted_date": "2026-03-31", "last_synced_at": "2026-10-15T00:03:05.400Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02051257" }, { "nct_id": "NCT00477412", "title": "Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Mantle Cell Lymphoma" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": 107, "start_date": "2007-04-03", "completion_date": "2020-10-28", "has_results": true, "last_update_posted_date": "2022-01-28", "last_synced_at": "2026-10-15T00:03:05.400Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00477412" }, { "nct_id": "NCT05064319", "title": "Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bipolar Disorder", "Cannabis Use", "Schizoaffective Disorder, Bipolar Type", "Bipolar I Disorder", "Bipolar II Disorder", "Cannabis Use Disorder, Mild", "Cannabis Use Disorder, Moderate", "Cannabis Use Disorder, Severe" ], "interventions": [ { "name": "Gabapentin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical University of South Carolina", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 51, "start_date": "2022-02-24", "completion_date": "2026-07-31", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-10-15T00:03:05.400Z", "location_count": 1, "location_summary": "Charleston, South Carolina", "locations": [ { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05064319" }, { "nct_id": "NCT00268853", "title": "A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Large-Cell Lymphoma" ], "interventions": [ { "name": "CPOP-R", "type": "DRUG" }, { "name": "CHOP-R", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CTI BioPharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 124, "start_date": "2005-11", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2024-05-30", "last_synced_at": "2026-10-15T00:03:05.400Z", "location_count": 58, "location_summary": "Concord, California • Hollister, California • La Jolla, California + 51 more", "locations": [ { "city": "Concord", "state": "California" }, { "city": "Hollister", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00268853" }, { "nct_id": "NCT00281801", "title": "Caregiver Support in the Quality of Life of Patients Who Are Undergoing Donor Bone Marrow Transplantation", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases", "Psychosocial Effects of Cancer and Its Treatment" ], "interventions": [ { "name": "psychosocial assessment and care", "type": "PROCEDURE" }, { "name": "Quality of Life Assessments", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 168, "start_date": "2006-02", "completion_date": "2010-04", "has_results": false, "last_update_posted_date": "2012-03-15", "last_synced_at": "2026-10-15T00:03:05.400Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00281801" }, { "nct_id": "NCT01767766", "title": "Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Hodgkin's Lymphoma", "Chronic Lymphocytic Leukemia", "Peripheral T-Cell Lymphoma", "Hodgkin's Lymphoma" ], "interventions": [ { "name": "TGR-1202", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TG Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2013-01-07", "completion_date": "2018-02", "has_results": false, "last_update_posted_date": "2021-08-23", "last_synced_at": "2026-10-15T00:03:05.400Z", "location_count": 7, "location_summary": "Sarasota, Florida • Hackensack, New Jersey • New York, New York + 4 more", "locations": [ { "city": "Sarasota", "state": "Florida" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01767766" }, { "nct_id": "NCT00003331", "title": "Combination Chemotherapy in Treating Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Precancerous Condition", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "fluorouracil", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "topotecan hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "1998-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2011-03-28", "last_synced_at": "2026-10-15T00:03:05.400Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003331" } ] }